Patents Assigned to University of Oulu
-
Patent number: 11926614Abstract: The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g.Type: GrantFiled: June 19, 2019Date of Patent: March 12, 2024Assignees: OSLO UNIVERSITETSSYKEHUS HF, FORSCHUNGSVERBUND BERLIN E.V., UNIVERSITY OF OULUInventors: Stefan Krauss, Marc Nazare, Lari Lehtio, Jo Waaler, Anita Wegert, Ruben Gerardus George Leenders
-
Patent number: 11096909Abstract: It is an aim of the present invention to provide inhibitors of human diphtheria toxin-like ADP-ribosyltransferases, such as ARTD10, for use as a medicine. It is another aim of the invention to provide compounds for use as human mono-ADP-ribosyltransferase (mARTD) inhibitors in vitro. In the present invention, it has been discovered that human ARTD10, which belongs to an enzyme family linked to cancer biology, can be specifically inhibited by the benzamide comprising compounds disclosed in the invention, such as 4,4?-oxydibenzamide.Type: GrantFiled: April 6, 2017Date of Patent: August 24, 2021Assignee: University of OuluInventors: Lari Lehtiö, Harikanth Venkannagari, Bernhard Lüscher, Patricia Verheugd
-
Publication number: 20180256089Abstract: An assessment method is disclosed to determine at least one of macro-topology, milli-topology, micro-topology and nano-topology of at least one interface of at least two media using topology of the interface. Topology information of the interface is processed by performing segmentation of volume information of the obtained information from background information of the obtained information. Reference surface information is generated and information on voids is obtained and analyzed to provide multivalued surface shape information. Quantitative mapping of the information on voids is performed using the multivalued surface shape information for determining at least one of macro-topology, milli-topology, micro-topology and nano-topology of the interface.Type: ApplicationFiled: May 11, 2018Publication date: September 13, 2018Applicant: University of OuluInventors: Heikki Nieminen, Tuomo Ylitalo, Simo Saarakkala, Edward Haeggström
-
Patent number: 9976164Abstract: The present invention relates to a method for producing a protein of interest containing one or more disulfide bonds in its native state. The method comprises that a prokaryotic host cell is genetically engineered to express the protein of interest and a sulfhydryl oxidase in the cytoplasm of the host cell. The protein of interest is formed in a soluble form and contains disulfide bonds due to the presence of the sulfhydryl oxidase in the cytoplasm of said host cell. The present invention relates also to a prokaryotic host cell and a vector system for producing a protein of interest containing natively folded disulfide bonds.Type: GrantFiled: December 9, 2015Date of Patent: May 22, 2018Assignee: University of OuluInventor: Lloyd Ruddock
-
Patent number: 9416388Abstract: The present invention relates to a method for producing natively folded disulfide bond containing proteins in a prokaryotic host. The method comprises that in the cytoplasm of a prokaryotic cell is expressed protein(s) of interest that naturally contain disulfide bonds and naturally occurring or inverted transmembrane enzyme, wherein the cysteines of the active site(s) are naturally or after genetic engineering located towards the prokaryotic cytoplasm. The enzyme is selected from the group of VKOR, inverted VKOR (iVKOR) and inverted Dsb B (iDsb B). In the prokaryotic cell is also expressed cytoplasmic DsbA or a corresponding protein being capable of providing electrons to the active site(s) of VKOR, iVKOR or iDsbB. The invention relates also to a prokaryotic host cell and a vector system for producing natively folded disulfide bond containing proteins.Type: GrantFiled: February 3, 2012Date of Patent: August 16, 2016Assignee: University of OuluInventors: Lloyd Ruddock, Feras Hatahet
-
Publication number: 20140342398Abstract: The present invention relates to a method for producing natively folded disulfide bond containing proteins in a prokaryotic host. The method comprises that in the cytoplasm of a prokaryotic cell is expressed protein(s) of interest that naturally contain disulfide bonds and naturally occurring or inverted transmembrane enzyme, wherein the cysteines of the active site(s) are naturally or after genetic engineering located towards the prokaryotic cytoplasm. The enzyme is selected from the group of VKOR, inverted VKOR (iVKOR) and inverted Dsb B (iDsb B). In the prokaryotic cell is also expressed cytoplasmic DsbA or a corresponding protein being capable of providing electrons to the active site(s) of VKOR, iVKOR or iDsbB. The invention relates also to a prokaryotic host cell and a vector system for producing natively folded disulfide bond containing proteins.Type: ApplicationFiled: February 3, 2012Publication date: November 20, 2014Applicant: UNIVERSITY OF OULUInventors: Lloyd Ruddock, Feras Hatahet
-
Publication number: 20140050674Abstract: This invention concerns a method of improving penetration of compositions to dentin, enamel, dental pulp or cement and dental compositions for restoration or decoration of teeth, for use in pulp medication comprising, for root canal disinfection and/or obturation and for desensitizing. This invention also concerns uses of DMSO for improving the bond strength of dental composition and in preparing dental compositions. Further the invention concerns a new method of treating teeth so that penetration of components is increased.Type: ApplicationFiled: April 30, 2012Publication date: February 20, 2014Applicant: University of OuluInventor: Leo Tjaderhane
-
Publication number: 20120202245Abstract: The present invention relates to a method for producing a protein of interest containing one or more disulfide bonds in its native state. The method comprises that a prokaryotic host cell is genetically engineered to express the protein of interest and a sulfhydryl oxidase in the cytoplasm of the host cell. The protein of interest is formed in a soluble form and contains disulfide bonds due to the presence of the sulfhydryl oxidase in the cytoplasm of said host cell. The present invention relates also to a prokaryotic host cell and a vector system for producing a protein of interest containing natively folded disulfide bonds.Type: ApplicationFiled: December 2, 2011Publication date: August 9, 2012Applicant: UNIVERSITY OF OULUInventor: Lloyd Ruddock
-
Patent number: 7776556Abstract: An improved method for diagnosing autoimmune or genetic diseases is provided in this disclosure. In particular, a method to diagnose diseases affecting the tissues of organs selected from the group of spleen, brain, heart, kidney, thyroid, eye, skin, intestine, liver, pancreas, adrenal gland, prostate and lungs or from the tissues selected from the group of muscles and bones or other tissues. More specifically, the present invention provides an improved method for diagnosing diseases affecting neuromuscular junctions.Type: GrantFiled: March 14, 2008Date of Patent: August 17, 2010Assignee: University of OuluInventors: Anne Heikkinen, Hongmin Tu, Taina Pihlajaniemi
-
Publication number: 20100124548Abstract: The present invention relates to methods and products for the treatment of any disorder or condition, which is associated with abnormal amount of non-collagenous protein, or abnormal oligomerization or dysfunction of non-collagenous protein, such as adiponectin in the blood circulation and/or tissue of a patient. The treatment comprises that functional form of the non-collagenous protein is adjusted in the blood circulation and/or tissue of the patient substantially to the level it is in the blood circulation and/or tissue of a healthy person, by using lysyl hydroxylase and/or glycosyl-transferase activities of LH3 or other lysyl hydroxylase to modify the non-collagenous protein to HMW or other functional form.Type: ApplicationFiled: October 29, 2009Publication date: May 20, 2010Applicant: University of OuluInventors: Raili Myllylä, Heli Ruoisalainen
-
Publication number: 20080227105Abstract: An improved method for diagnosing autoimmune or genetic diseases is provided in this disclosure. In particular, a method to diagnose diseases affecting the tissues of organs selected from the group of spleen, brain, heart, kidney, thyroid, eye, skin, intestine, liver, pancreas, adrenal gland, prostate and lungs or from the tissues selected from the group of muscles and bones or other tissues. More specifically, the present invention provides an improved method for diagnosing diseases affecting neuromuscular junctions.Type: ApplicationFiled: March 14, 2008Publication date: September 18, 2008Applicant: University of OuluInventors: Anne Heikkinen, Hongmin Tu, Taina Pihlajaniemi
-
Patent number: 6265157Abstract: Compositions and methods useful for determining whether a subject has an alteration in a gene encoding a protein chain of Type I or Type IX collagen are described. Novel intronic sequences of five human genes, COL1A1, COL1A2, COL9A1, COL9A2, and COL9A3 are described. Methods of determining the existence in a subject of a pathological condition associated with an altered gene encoding a Type I or Type IX collagen protein chain are provided, wherein such pathological conditions include diseases and disorders which are known to be associated with an altered gene encoding a Type I or Type IX collagen protein chain. Primers, probes, and methods of detecting a genetic predisposition of a subject for a pathological condition associated with an altered gene encoding a Type I or Type IX collagen protein chain are provided.Type: GrantFiled: October 3, 1997Date of Patent: July 24, 2001Assignees: Allegheny University of the Health Sciences, Thomas Jefferson University, University of OuluInventors: Darwin J. Prockop, Loretta D. Spotila, Constantinos D. Deltas, Larisa Sereda, Andrea Westerhausen Larson, Michael Pack, Alain Colige, James Early, Jarmo Körkkö, Leena Ala-Kokko, Susanna Annunen, Tero Pihlajamaa, Mirko Vuoristo, Petteri Paassilta